Maître de conférences
UFR SMBH, Laboratoire CB3S, ChemPhosBio, Bureau 337
1 Rue de Chablis - 93017 Bobigny (France)
This email address is being protected from spambots. You need JavaScript enabled to view it.
+33 (0)1 48 38 77 39
Biography
Thibaut LEGIGAN studied chemistry at the University of Poitiers (France) and obtained his PhD in 2012 under the supervision of Prof. Sébastien PAPOT. The subject of his thesis was the study of new drug delivery systems for cancer chemotherapy. Then, he joined successively the University College Cork (Prof. Anita R. MAGUIRE, Ireland), the University of Poitiers (Prof. Yves BLÉRIOT, France) and the University of Montpellier (Dr. Frédéric COUTROT, France) as a post-doctoral researcher. In 2017, Thibaut was appointed Assistant Professor at University Paris 13. His research interests include the synthesis of bioactive compounds and the design of drug delivery systems for cancer chemotherapy.
Research Topics
Organic Chemistry, methodological development, Synthesis and vectorization of phosphonylated molecules.
Significant Publications
Synthesis and preliminary anticancer evaluation of photo-responsive prodrugs of hydroxymethylene bisphosphonate alendronate. Descamps, A.; Arnoux, P.; Frochot, C.; Barbault, F.; Deschamp, J.; Monteil, M.; Migianu-Griffoni, E.; Legigan, T.; Lecouvey, M. Eur. J. Med. Chem. 2024, 269, 116307. https://doi.org/10.1039/D3NJ04980A
Synthesis of Aminobisphosphinates through a Cascade Reaction between Hypophosphorous Acid and Bis(trimethylsilyl)imidates Mediated by ZnI2. Ayadi, N.; Descamps, A.; Legigan, T.; Dussart-Gautheret, J.; Monteil, M.; Migianu-Griffoni, E.; Ben Ayed, T.; Deschamp, J.; Lecouvey, M. . Molecules 2023, 28. 10.3390/molecules28176226 This article belongs to the Special Issue "Recent Progress in Organophosphorus Chemistry"
Synthesis and Preliminary Anticancer Evaluation of New Triazole Bisphosphonate-based Isoprenoid Biosynthesis Inhibitors. T. Legigan, E. Migianu-Griffoni, M.A. Abdenour, A. Descamps, J. Deschamp, O. Gager, M. Monteil, F. Barbault, M. Lecouvey, Eur. J. Med. Chem. 2021, 214,133241. DOI : 10.1016/j.ejmech.2021.113241.
An enzyme-responsive drug delivery system targeting the tumor microenvironment for efficient therapy of breast and pancreatic cancers: B. Renoux, F. Raes, T. Legigan, E. Péraudeau, B. Eddhif, P. Poinot, I. Tranoy-Opalinski, J. Alsarraf, O. Koniev, S. Kolodych, S. Lerondel, A. Le Pape, J. Clarhaut, S. Papot Chem. Sci., 2017, 8, 3427-3433.
Active esters as pseudostoppers for slippage synthesis of [2] pseudorotaxane building blocks: a straightforward route to multi-interlocked molecular machines: T. Legigan, B. Riss-Yaw, C. Clavel, F. Coutrot Chem. Eur. J., 2016, 22, 8835-8847.
A mechanically interlocked molecular system programmed for the delivery of an anticancer drug: R. Barat, T. Legigan, I. Tranoy-Opalinski, B. Renoux, E. Péraudeau, J. Clarhaut, P. Poinot, A. E. Fernandes, V. Aucagne, D. A. Leigh, S. Papot Chem. Sci., 2015, 6, 2608-2613.
The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumours in prodrug monotherapy: T. Legigan, J. Clarhaut, I. Tranoy-Opalinski, A. Monvoisin, B. Renoux, M. Thomas, A. Lepape, S. Lerondel, S. Papot Angew. Chem. Int. Ed. 2012, 46, 11606-11610.
Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin: T. Legigan, J. Clarhaut, B. Renoux, I. Tranoy-Opalinski, A. Monvoisin, J.-M. Berjeaud, F. Guilhot, S. Papot J. Med. Chem. 2012, 55, 4516-4520.
Patent
Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires. B. Renoux, I. Opalinski, T. Legigan, S. Papot WO 2015/118497Al, 13 août 2015
Teaching
PACES (1st year of medical school), Bachelor in Science of Life (L1, L2, L3)